600161 天坛生物
2026/03 - 三个月
人民幣(K¥)
与去年同期
比较
2025/12
人民幣(K¥)
2024/12
人民幣(K¥)
2023/12
人民幣(K¥)
2022/12
人民幣(K¥)
营业总收入1,141,704-13.36%6,168,0366,031,8655,180,4424,261,305
减:营业总成本949,2444.54%4,315,5093,517,6813,429,7642,906,794
    其中:营业成本746,7764.70%3,463,2322,732,4402,550,7212,170,024
               财务费用370-125.29%(2,061)(32,914)(49,525)(57,989)
               资产减值损失(1,925)10.17%(19,111)(53,018)(2,167)(2,254)
公允价值变动收益------------
投资收益5,521-38.37%26,97963,92737,21328,127
    其中:对联营企业和合营企业的投资收益------------
营业利润223,389-45.01%1,837,3082,557,7851,804,9951,432,115
利润总额223,217-45.06%1,822,7242,547,2181,798,5981,426,273
减:所得税费用44,124-36.05%332,842434,953289,140221,598
净利润179,093-46.90%1,489,8822,112,2651,509,4591,204,675
减:非控股权益53,227-42.85%399,044563,100399,570323,758
股东净利润125,866-48.45%1,090,8381,549,1651,109,889880,916

市场价值指针
每股收益 (元) *0.060-50.00%0.5500.7800.5600.530
每股派息 (元) *----0.2000.1000.1500.050
每股净资产 (元) *5.9994.22%5.9355.6335.9615.340
审计意见 #--标准无保留意见标准无保留意见标准无保留意见标准无保留意见
回页顶
备注: *未调整数据
#只提供简体内容